RBC Capital analyst Frank Morgan maintained a Buy rating on Humana Inc (NYSE:HUM) on Wednesday, setting a price target of $479, which is approximately 3.46% above the present share price of $463.
Morgan expects Humana Inc to post earnings per share (EPS) of $6.42 for the second quarter of 2021.
The current consensus among 11 TipRanks analysts is for a Moderate Buy rating of shares in Humana, with an average price target of $487.64.
The analysts price targets range from a high of $525 to a low of $431.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $20.67 billion and a net profit of $0. The company's market cap is $59.73 billion.
According to TipRanks.com, RBC Capital analyst Frank Morgan is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 23.7% and a 70.83% success rate.
Humana Inc. is a leading health insurance service provider in the United States. The company, through its Retail division, provides medicare benefits and state-based medicaid contracts, which are marketed on a retail basis to individuals. The Group and Specialty business offers employer group commercial fully-insured medical products and specialty health insurance benefits. Humana offers pharmacy solutions, provider services, home-based services, and clinical programs to the company’s health plan members as well as to third parties through the Healthcare Services (NASDAQ:HCSG) segment.